The entry of insulin biosimilars, such as biosimilar insulin glargine, into the National Health System contributes to the sustainability of the system and allows pharmaceutical spending to be reduced, without losing quality, which facilitates greater accessibility to treatments.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
